QUIRIS Healthcare Germany, Am Kreuzkamp 5-7, D-33334 Gütersloh, Germany.
Expert Rev Clin Pharmacol. 2013 Jul;6(4):367-8. doi: 10.1586/17512433.2013.811271.
The paper by Merchant et al. demonstrates that the pharmacokinetic profile of melatonin differs in preterm infants from that of adults. The findings of this study can guide the necessary future preventive and therapeutic clinical trials on melatonin in preterm infants. These studies are urgently needed to further evaluate the protective potential of melatonin in preterm infants. Melatonin acts as a potent endogenous antioxidant agent that antagonizes oxidative stress, and melatonin replacement therapy could thereby prevent the development of many disorders and diseases that can afflict preterm infants such as sepsis, asphyxia, respiratory distress or surgical complications. Since preterm infants are melatonin deficient, administration of the compound may provide the necessary levels to assure their health and well-being. Pharmacokinetic data such as those provided in the evaluated paper are necessary to establish safe and efficient melatonin treatment regimens in this highly susceptible population.
梅彻特等人的论文表明，褪黑素在早产儿中的药代动力学特征与成人不同。这项研究的结果可以为未来在早产儿中进行关于褪黑素的预防性和治疗性临床试验提供指导。这些研究对于进一步评估褪黑素对早产儿的保护潜力非常必要。褪黑素是一种有效的内源性抗氧化剂，可以对抗氧化应激，因此褪黑素替代疗法可以预防许多可能影响早产儿的疾病和疾病的发展，如败血症、窒息、呼吸窘迫或手术并发症。由于早产儿缺乏褪黑素，因此给予该化合物可能会提供必要的水平以确保其健康和幸福。像评估论文中提供的药代动力学数据对于在这个高度敏感的人群中建立安全有效的褪黑素治疗方案是必要的。
